Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
October 05, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative...
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
June 15, 2023 08:00 ET
|
Impel Pharmaceuticals
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given...
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 08:00 ET
|
Impel Pharmaceuticals
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor...
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering...
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
May 05, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
April 26, 2023 08:00 ET
|
Impel Pharmaceuticals
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301...
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
April 12, 2023 16:01 ET
|
Impel Pharmaceuticals
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting
April 11, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 24, 2023 08:17 ET
|
Impel Pharmaceuticals
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to...
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
March 17, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...